The Filing Desk

IDEAYA Biosciences vs Puma Biotechnology

IDEAYA Biosciences IDYA · Puma Biotechnology PBYI · Pharmaceuticals

Puma Biotechnology reported revenue of $228 million in fiscal 2025, about the same as IDEAYA Biosciences' $219 million in fiscal 2025. IDEAYA Biosciences' revenue grew 3024.4% in its latest year, and Puma Biotechnology's fell 0.9%. IDEAYA Biosciences had an operating margin of -72.8%, against 16.3% at Puma Biotechnology. Free cash flow was −$73 million at IDEAYA Biosciences and $42 million at Puma Biotechnology.

Side by side

IDEAYA BiosciencesPuma Biotechnology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$219M$228M
Revenue growth3,024.4%−0.9%
Revenue growth a year, last 5 years62.2%0.3%
Gross margin—74.5%
Operating margin−72.8%16.3%
Net margin−52.0%13.6%
Free cash flow−$73M$42M
Free cash flow margin−33.6%18.3%
Return on capital—48.2%
Net debt to EBITDA—−1.4x
Dividends and buybacks$0M$0M
Change in diluted share count8.3%3.2%
Last close$31.83$7.77
P/E at the last close—16.9×
Insider trades, last 12 monthsbought $1.6 million, sold $382,096—
Piotroski F-score—8 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
IDEAYA BiosciencesPuma Biotechnology
Operating margin
Percent of revenue
IDEAYA BiosciencesPuma Biotechnology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
IDEAYA BiosciencesPuma Biotechnology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the IDEAYA Biosciences and Puma Biotechnology pages.